报告时间：2024年12月9日(周一) 15:00-17:00

报告地点：生物学院1313会议室（惟德楼13层）

报 告 人：Dr. Kit S Lam

报告主题：From combinatorial chemistry to nanomedicine

报告人简介：Dr. Kit S Lam is a physician-scientist and an expert in combinatorial chemistry, peptide chemistry, chemical biology, drug discovery and development, molecular imaging, nanotherapeutics, biomaterial and medical oncology. He obtained his B.A. in Microbiology in 1975 at the University of Texas at Austin, his Ph.D. in Oncology in 1980 from McArdle Laboratory for Cancer Research, University of Wisconsin, and his M.D. in 1984 from Stanford University School of Medicine. He is board certified in both Internal Medicine and Medical Oncology. Dr. Lam is recognized as one of the pioneers who started the field of synthetic combinatorial chemistry in the late 1980s and early 1990s. He conceived the one-bead one-compound (OBOC) concept and invented the OBOC combinatorial library methods that have been used by many investigators around the world for basic research, drug discovery and material discovery. More recently, the OBOC concept has been successfully applied by the molecular biologists for the generation of DNA barcodes for single cell genomic analysis. The OBOC combinatorial library method was first published in Nature in 1991. The article has since been cited over 2,500 times. In the last 15 years, Dr. Lam has expanded his research program into nanomedicine. He has developed several nanoplatforms for targeted drug delivery: telodendrimer based micellar nanoparticles, receptor-mediated transformable peptide nanoparticles and PVA-pheophorbide-catechol nanoplatform for covalent drug loading. Very recently, he succeeded in using in vivo click chemistry as a novel approach for highly specific nanodelivery. His Biomaterial article on surface charge effects of telodendrimer-based micellar nanoparticles on in vivo delivery has been cited over 1000 times.

报 告 人：Dr. Yuanpei Li

报告主题：Transformative nanomedicine: from bench to clinic

报告人简介：Dr. Yuanpei Li started his independent research career as an Assistant Professor in the Department of Biochemistry and Molecular Medicine at University of California, Davis (UC Davis) in 2016. He was promoted to Full Professor in 2021. Li lab is interested in developing innovative nanomedicine, cancer therapeutics and molecular imaging agents that will have a tremendous impact on the treatment of cancer and other diseases.  The work in these areas has resulted in over 100 publications in leading journals, such as Nature Nanotechnology, Advanced Materials, and Nature Communications. Dr. Li is the co-inventor of over 10 patents and patents applications. He has successfully translated several novel cancer therapeutics into first in human clinical trials. Dr. Li's research program is well funded by the National Institute of Health (NIH) and Department of Defense (DoD) (~$20 million). He has been the Principal Investigator on 7 NIH R01 grants. Dr. Li is currently a Standing Member of the Advancing Therapeutics A (ATA) Study Section at NIH. He is a founding committee member of the Center for Experimental Therapeutics in Cancer at UC Davis. Dr. Li was elected as a College of Fellow at the American Institute for Medical and Biological Engineering (AIMBE) in 2022 for outstanding contributions to the development of intelligent nanomedicine platforms to improve drug delivery. He is the recipient of a series of awards including the latest 2024 Joan Oettinger Memorial Award.

        欢迎广大师生参加！

生物工程学院

2024年12月6日